David Putrino | International ME/CFS Conference 2025: Low-dose Rapamycin for Long COVID скачать в хорошем качестве

David Putrino | International ME/CFS Conference 2025: Low-dose Rapamycin for Long COVID

Prof David Putrino presented a clinical trial on rapamycin (sirolimus) in Long COVID. Rapamycin is a macrocyclic antibiotic and also an m-TOR inhibitor, which has an immunosuppressive effect in high doses. A currently conducted randomised, controlled, double-blind study with 80 Long COVID patients is investigating the efficacy of single weekly doses over a period of three months. The goal is to identify suitable biomarkers of treatment-responsive subjects and then plan a larger study. 🔗 More Details: https://events.mecfs-research.org/en/... 🔔 Subscribe to our channel so you won’t miss any updates or presentations from the International ME/CFS Conference 2025! Other interesting links: 👉 Report on the societal costs of ME/CFS and Long COVID in Germany: https://mecfs-research.org/costreport... 👉 Official Website of the International ME/CFS Conference 2025: https://events.mecfs-research.org/en/... 👉 ME/CFS Research Register: https://mrr.mecfs-research.org/